Filing Flows › Mimedx Group (MDXG) › Q3 2026
Mimedx Group (MDXG) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
Mimedx Group (MDXG) reported revenue of $62.3M for the third quarter 2026 (Q3 2026), -45% from a year earlier and -3% from the quarter before. Operating margin was -18.8%, net loss $8.7M (13.9% of revenue).
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $62.3M | -3% | -45% |
| Operating profit | −$11.7M | — | -153% |
| Net earnings | −$8.7M | — | -152% |
| Operating cash flow | $3.9M | — | -87% |
| Free cash flow | $3.8M | — | -87% |
What changed
Revenue was $62.3M in Q3 2026, down 45% year over year and down 3% from the previous quarter. Surgical was the largest line at 64% of revenue. Wound lost $54.8M year over year (down 71%), 106% of the total change.
Gross margin was 79.8%, down 3.7 points from Q3 2025. Operating costs exceeded revenue by $11.7M, an operating margin of -18.8%. Operating expenses fell 16% while revenue fell 45%. The quarter ended with a net loss of $8.7M, narrower than the previous quarter's $14.8M loss.
Operating cash flow was $3.9M (down 87% year over year). Non-cash charges added back $665K of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $8.7M. Capital expenditures of $166K left free cash flow of $3.8M.
Questions
What was Mimedx Group's revenue in the third quarter 2026?
Mimedx Group (MDXG) reported revenue of $62.3M for the third quarter 2026 (Q3 2026), -45% from a year earlier and -3% from the quarter before.
Was Mimedx Group profitable in the third quarter 2026?
Operating loss was $11.7M (-18.8% of revenue) and net loss $8.7M.
Source: Mimedx Group 10-Q on SEC EDGAR.